Now Recruiting: Sarcoma Clinical Trials
As a National Cancer Institute-designated comprehensive cancer center, City of Hope's sarcoma cancer program is a nationally recognized leader in the research and treatment of sarcomas. As a cancer center whose primary focus is cancer treatment and care, City of Hope has been named one of America's top cancer hospitals by U.S. News & World Report for over a decade, with our physicians consistently being named among "America's Top Doctors" by Castle Connolly.
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.
Soft Tissue Sarcoma
NCT04339738: Principal investigator is actively recruiting patients for a Phase 2 clinical trial studying the benefits of the addition of nivolumab to chemotherapy in patients with soft tissue sarcoma.
Patient Enrollment Qualifications
- 18 years of age or older
- Histologically confirmed cutaneous or visceral angiosarcoma, where curative treatment is either not possible or curative modality therapy is declined
- Eastern Cooperative Oncology Group performance status 0-1
Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
NCT04200443: Principal investigator is now enrolling patients facing unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas for a study on the benefits of cabozantinib and temozolomide during treatment.
- 18 years of age or older
- A confirmed diagnosis of unresectable or metastatic: Uterine and nonuterine leiomyosarcoma or Other soft tissue sarcoma (nonleiomyosarcoma)
- An Eastern Cooperative Oncology Group performance status of 0-1
Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT04044768: Principal investigator is now enrolling patients in a Phase 1 study on the efficacy and safety of ADP-A2M4 in HLA-A *02 eligible and MAGE-A4 positive patients with metastatic or inoperable synovial sarcoma or myxoid round cell liposarcoma (MRCLS).
- Age 16 to 75 years of age
- Confirmed diagnosis of advanced synovial sarcoma or myxoid liposarcoma/MRCLS.
- Measurable disease according to RECIST v1.1
Advanced Sarcoma Harboring Alterations
NCT04595747: Principal investigator is actively recruiting patients for a Phase 2 study on the benefits of rogaratinib in treating patients with sarcoma that has a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST).
Patient Enrollment Qualifications
- 18 years of age or older
- Confirmed sarcoma with FGFR alteration identified by next-generation sequencing profiling, with the exception of SDH-deficient GIST who can be enrolled regardless of FGFR status
- Eastern Cooperative Oncology Group performance status of ≤ 2